iShares S&P 500 Growth
Latest iShares S&P 500 Growth News and Updates
Company & Industry Overviews Nike Market Share Gets the High Score in Activewear
UA’s market share came in at 6%, and ADDYY’s came in at 3%. Hanes (HBI) took 3% of the market in 1Q15 .Nike (NKE) was the market leader for activewear overall.Company & Industry Overviews US Large-Cap Equity Funds: Is Active or Passive Investment Best?
Except for one fund (MIGFX), no other actively managed fund that we have reviewed in this series has been able to outperform the passively managed SPY.Company & Industry Overviews PepsiCo Partners with Starbucks to Seek Growth in Latin America
In 2016, PepsiCo and Starbucks will distribute Starbucks’s ready-to-drink, or RTD, coffee and energy beverages in select Latin American markets.Consumer Productivity Enhancements: How Home Depot Is Trimming the Fat
Productivity enhancements resulted in improved profitability margins for the world’s number one retailer.Consumer How Much Has Under Armour Increased Revenue Guidance?
Under Armour raised the higher end of its 2016 operating income estimate to $503 million–$507 million, implying a growth rate of 23.1%–24.1% over 2015.Company & Industry Overviews Why Is Foot Locker Eyeing Higher Growth in Europe?
Foot Locker (FL) made about 28.4% of its sales, or $2.1 billion, from outside the United States in fiscal 2016.Consumer The Catalysts Powering Nike’s Growth Performance in Fiscal 2016
Nike (NKE) is expected to post sales of $8.3 billion in fiscal 4Q16, an increase of 6.4% year-over-year, according to the Wall Street analysts’ consensus.Company & Industry Overviews How Incyte’s Jakafi Performed in 3Q17
Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.Company & Industry Overviews New Data Confirms the Efficiency of BSX’s HeartLogic Diagnostic
On September 19, 2017, Boston Scientific announced new data from its MultiSENSE (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) study.Company & Industry Overviews Phase 3 Trials Show Elagolix’s Efficacy for Endometriosis Pain
AbbVie (ABBV) and Neurocrine Biosciences (NBIX) have completed two phase 3 trials to evaluate the efficacy and safety of Elagolix as a treatment option for reducing pain associated with endometriosis as compared to a placebo.Earnings Report Here’s What’s Driving Medtronic’s MITG Segment
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues.Company & Industry Overviews Exploring the Nuances of Stryker’s Cost Transformation for Growth
Cost transformation growth is one of Stryker’s key strategies for driving growth. The company has come a long way from its decentralized structure prior to 2010.Company & Industry Overviews Bernstein: Excess Risk Aversion Has Made Investors ‘Wallflowers’
In his November Insights newsletter, Richard Bernstein stated, “It is incredible that investors have basically been wallflowers during the second longest bull market of the post-war period.”Macroeconomic Analysis How the Next President Could Shape US Monetary Policy
The Federal Reserve’s second last meeting of 2016 is now over, leaving only one meeting left in which the central bank can enact a rate hike.Macroeconomic Analysis Why Were Fed Policymakers Worried about Clear Communication?
The credibility of the Federal Reserve was a concern raised by some policymakers at the September FOMC (Federal Open Market Committee) meeting.Company & Industry Overviews How GILD Plans to Battle through Impending HIV Patent Cliff
Gilead Sciences (GILD) is the leading biotechnology player in the global HIV market.Company & Industry Overviews How Gilead Dominates the HCV Space
In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.Company & Industry Overviews Can Thermo Fisher’s PPI Business System Continue to Drive Growth in 2016?
The PPI system has helped nourish strong top-line growth across Thermo Fisher’s businesses while boosting margins.Company & Industry Overviews What Drives Medtronic’s Cardiac Vascular Group’s Revenues?
Medtronic’s (MDT) Cardiac and Vascular Group (or CVG) is its largest segment.Company & Industry Overviews Understanding Trinity: Inside the Testing of AbbVie’s Rova-T
Trinity is a phase-2 clinical trial that tests the use of Rova-T as a third-line therapy for SCLC (small cell lung cancer).Earnings Report PepsiCo’s Non-Carbonated Beverages Sparkle in 1Q16
In 1Q16, PepsiCo’s North America Beverages segment accounted for 36.8% of the company’s net revenue and 27.5% of the division’s total operating profit.Company & Industry Overviews Romosozumab: Will It Benefit Amgen in the Future?
In 1Q16, Amgen expects to have data from its Phase 3 clinical trial exploring the use of innovative drug romosozumab for treating post-menopausal osteoporosis.Company & Industry Overviews Breaking down Stryker’s MedSurg Segment
Stryker’s MedSurg segment reported an increase of 10.8% in net sales in 2014, driven by increased demand in instruments, medical products, and acquisitions.Company & Industry Overviews Understanding the Geographical Segmentation of Stryker
While Stryker is a global medical tech company focused on expanding its presence across international markets, the US makes up ~68% of its total revenues.Company & Industry Overviews Understanding Coca-Cola’s New Marketing Efforts
Coca-Cola (KO) is using its productivity savings to ramp up its media investments.Earnings Report Celgene Has a Strong Inflammation and Immunology Pipeline
In 3Q15, Celgene had a strong inflammation and immunology pipeline. The company witnessed the progress of its key investigational drug GED-0301.Company & Industry Overviews Understanding Ross Stores’ Business Model
Ross Stores operates under two trademarks: Ross Dress for Less and dd’s DISCOUNTS. There are 1,259 Dress for Less and 165 dd’s DISCOUNTS stores in the US.Macroeconomic Analysis P&G’s Grooming and Hair Care Brands Lead Market
P&G’s Gillette, Fusion, and Venus are its largest male and female grooming brands. It has continued to grow with ProGlide and FlexBall in the US.Company & Industry Overviews Obstacles to Altria Group’s Growth: Weaknesses and Threats
Altria’s business faces threats of high scrutiny, taxation, and regulation. Prohibitions on cigarette sales and smoking bans in public places affect sales.Macroeconomic Analysis Colgate’s Efforts to Engage Consumers to Build Brand Awareness
In order to attract consumers in retail stores, Colgate has increased its commercial investment in advertising, promotions, trade spending, and creative brand building.Earnings Report Overseas Markets and Nike: Obstacles on the Leading Footwear Company’s Revenue Racetrack?
In fiscal 2015, Nike derived ~55% of its sales from overseas markets—18.7% from Western Europe, 12.7% from Emerging Markets, and 10% from Greater China.Company & Industry Overviews Disney’s ESPN: Revenues under Competitive Pressure
ESPN is a part of Disney’s Media Networks segment. Affiliate fees are major component of this segment and are under pressure due to subscriber loss.Company & Industry Overviews Assessing Estée Lauder’s Strengths and Opportunities
Estée Lauder’s large geographical footprint diversifies its revenue stream, which is one of its chief strengths.Company & Industry Overviews Estée Lauder’s Most Promising Brands
Catering to the premium market, Estee Lauder’s heritage brands include Aramis and Designer Fragrances, Clinique, and Origins.Company & Industry Overviews Discovering VF Corp.’s Marketing Edge
VFC’s marketing dollars are designed to get the most returns from its stores, other retailers (wholesale customers), and its e-commerce websites.Company & Industry Overviews Under Armour’s Cost Profile And Outlook
Under Armour, Inc.’s cost of goods sold margins have been fairly steady over the years. SG&A costs are likely to trend higher in the near to medium term.Company & Industry Overviews Understanding The Under Armour Growth Story
Under Armour’s stock price growth has been phenomenal—up by over 10x in the last five years. This dwarfs the ~200% increase seen by market leader NIKE.